Kenzen Raises $5 Million to Fuel Precision Health Platform Featuring Smart Wearables

SAN FRANCISCO--(BUSINESS WIRE)--Kenzen, an innovator of wearables for precision health, today announced it has raised $5 million from multiple investors to further development, support and market positioning of its ECHO Smart Patch wearable technology. Kenzen’s smart wearable patch continuously uses non-invasive sweat analysis to measure vital signs and motion sensors to predict and prevent avoidable injuries and illness.

Kenzen’s strategic investors include Digitalis, Flex (formerly Flextronics), the San Francisco 49ers, Hickory Ventures, Gaingels, and the Women’s Capital Connection.

Kenzen’s ECHO Smart Patch represents the future of wearable biosensors, offering an advanced personal health platform. Kenzen takes a non-invasive approach via the ECHO Smart Patch, a small, connected wearable that, in combination with mobile apps and proprietary algorithms, generates around-the-clock health analysis and meaningful, actionable insights with personalized health relevance.

Founded in 2014, Kenzen has been recognized by leading media players TechCrunch*, TechNavio,** Fast Company,*** and Google for Entrepreneurs**** for its wearable innovations.

Executive Perspectives:

Steve Allen, Co-founder and Partner, Digitalis Ventures

“Technology continually improves people’s lives and wearables represent the next great shift that will boost precision medicine. Digitalis recognizes that Kenzen, led by its dynamic executive team, is in great position to address digital health initiatives promoting wellness and safety.”

Paraag Marathe, Chief Strategy Officer / EVP of Football Operations, San Francisco 49ers

“Kenzen has tremendous technology that can help sports teams, and impact fitness and health overall. As both an investor and customer, we are big fans of Kenzen and appreciate the team’s down-to-earth, honest and very intellectual approach to things. They’ve been a great partner in building a breakthrough product for athletes.”

Dr. Sonia Sousa, Co-Founder and CEO, Kenzen

“Kenzen brings connected, clinical relevance to wearables by measuring and delivering predictive analytics that are critical to wellness and can improve physical performance. We are marrying connected wearables with fluidics analysis to deliver real-time precision medicine to healthcare communities.”

About Kenzen

Kenzen is a developer of a next-generation wearables platform that continuously monitors, predicts and prevents avoidable health conditions using non-invasive sweat analysis. Kenzen’s award-winning ECHO Smart Patch wearable uses multiple patented biosensors to continuously measure vital health signs and gather reliable data to prevent injuries, illness and to optimize health. Awarded in the “Future Athlete” category by the NFL, TechCrunch and Stanford, and named the Judges’ Favorite at the 2017 Google Demo Day in Europe, and awarded as a finalist for Fast Company Magazine’s World Changing Ideas Awards in the health category, Kenzen is advancing precision medicine through its wearable platform with real-time information that is clinically relevant, meaningful to consumers and game-changing for athletes and industrial workforces. For more information, please visit: www.kenzen.com

* Winner of Best Startup in the Future Athlete category at the NFL’s 1st and Future, co-hosted by Stanford University and TechCrunch, 2016

** Recognized as key player in the Smart Wearable Patch market by Technavio, “Global Wearable Patch Market 2016--2020” Market Research Report, November 2016

***Awarded as a Finalist in the Health category of Fast Company’s World Changing Ideas Awards for 2017

****Selected as the Judges’ Favorite by Google at inaugural Google Demo Day Europe in London.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.